Tumor lysis with LTX-401 creates anticancer immunity

Tumor lysis with LTX-401 creates anticancer immunity

Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401,...

Full description

Bibliographic Details
Main Authors: Wei Xie, Laura Mondragón, Brynjar Mauseth, Yan Wang, Jonathan Pol, Sarah Lévesque, Heng Zhou, Takahiro Yamazaki, Johannes J. Eksteen, Laurence Zitvogel, Baldur Sveinbjørnsson, Øystein Rekdal, Oliver Kepp, Guido Kroemer
Format: Article
Language:English
Published: Taylor & Francis Group 2019-07-01
Series:OncoImmunology
Subjects:
oncolysis
anticancer therapy
immunogenic cell death
checkpoint blockade
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1594555

Internet

http://dx.doi.org/10.1080/2162402X.2019.1594555

Similar Items